PGNY vs. SHC, AGL, TVTY, ARA, VMD, CO, OTRK, MGRX, MRAI, and BRTX
Should you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Sotera Health (SHC), agilon health (AGL), Tivity Health (TVTY), American Renal Associates (ARA), Viemed Healthcare (VMD), Global Cord Blood (CO), Ontrak (OTRK), Mangoceuticals (MGRX), Marpai (MRAI), and BioRestorative Therapies (BRTX).
Progyny (NASDAQ:PGNY) and Sotera Health (NASDAQ:SHC) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations.
Progyny has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Sotera Health has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.
Progyny has higher revenue and earnings than Sotera Health. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
94.9% of Progyny shares are owned by institutional investors. Comparatively, 91.0% of Sotera Health shares are owned by institutional investors. 12.3% of Progyny shares are owned by insiders. Comparatively, 55.1% of Sotera Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Progyny had 6 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Progyny and 2 mentions for Sotera Health. Progyny's average media sentiment score of 1.14 beat Sotera Health's score of 0.96 indicating that Progyny is being referred to more favorably in the media.
Progyny has a net margin of 5.53% compared to Sotera Health's net margin of 5.09%. Sotera Health's return on equity of 48.47% beat Progyny's return on equity.
Progyny received 42 more outperform votes than Sotera Health when rated by MarketBeat users. Likewise, 75.00% of users gave Progyny an outperform vote while only 56.25% of users gave Sotera Health an outperform vote.
Progyny presently has a consensus price target of $43.11, indicating a potential upside of 63.92%. Sotera Health has a consensus price target of $16.92, indicating a potential upside of 54.63%. Given Progyny's stronger consensus rating and higher possible upside, equities research analysts clearly believe Progyny is more favorable than Sotera Health.
Summary
Progyny beats Sotera Health on 13 of the 18 factors compared between the two stocks.
Get Progyny News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
